A previously well-characterized CCK2R antibody [19,20] revealed some level of CCK2R expression by tumor cells in 15 out of the 18 MM patients compared with 2 out of the 10 BCC patients used as controls (Figure 1B). Here, CCKBR is linked to Miyoshi myopathy.